Study of Platelet Activation in Septic Shock Patients
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Septic Shock
- 发起方
- University Hospital, Toulouse
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Level of platelets activation markers expression (CD62-P, antibody CD63, CD42b)
- 状态
- 已完成
- 最后更新
- 4个月前
概览
简要总结
Some studies have shown that antiplatelets agents could reduce organ dysfunction in septic shock in mice and human models. Platelets are actors in immunity and their activation can be complicated by tissue damage with vascular occlusions which can lead to organ dysfunction. Investigators can hypothesize an increase in platelet activation and in leukocyte-platelet aggregates in septic shock.
研究者
入排标准
入选标准
- •EXPERIMENTAL GROUP
- •Patient who possibly gave an oral agreement to inclusion and may sign a consent once out of intensive care
- •Patients hospitalized in general intensive care
- •Patient hospitalized for less than 72 hours
- •Patient suffering from severe sepsis, whatever their origin, with hypotension (PAs \<90mmHg) despite adequate fluid resuscitation and vasoactive requiring the use of amines, with hypoperfusion and / or at least one organ dysfunction ( septic shock)
- •Patient with a Sequential Organ Failure Assessment (SOFA) score\> 8 (or\> 2 in an organ) in the first 24 hours
- •Patient enjoying a social security scheme or equivalent
- •CONTROL GROUP
- •Signed informed consent
- •Patient seen anesthesia consultation for orthopedic knee prosthesis of laying or hip with a negative balance infectious
排除标准
- •EXPERIMENTAL GROUP
- •Patient on safeguarding justice, guardianship
- •Patient suffering from a haematological malignancy (leukemia, lymphoma ...)
- •Patient suffering from thrombocytopenia or constitutional thrombopathy
- •CONTROL GROUP
- •Patient on safeguarding justice, guardianship
- •Patient with infectious positive balance (dental, urinary tract) prior to surgery
- •Patient suffering from a haematological malignancy (leukemia, lymphoma ...)
- •Patient suffering from thrombocytopenia or constitutional thrombopathy
结局指标
主要结局
Level of platelets activation markers expression (CD62-P, antibody CD63, CD42b)
时间窗: T0 at the admission in intensive care unit
Specific platelet activation markers and circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit for patients in test group and during the orthopedic surgical anesthesia consultation for patients in control group.
Level of platelets activation markers expression (CD62-P, CD63, CD42b)
时间窗: T48 hours after admission in intensive care unit
Specific platelet activation markers and circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood 48 hours later admission in intensive care unit only for patients in test group.
次要结局
- Correlation of leukocyte-platelet aggregates rate and septic shock severity.(T0 at the admission in intensive care unit)
- Comparison of platelet activation in subjects treated or not with antiplatelet agents.(T0 at the admission in intensive care unit)
- Rate of leukocyte-platelet aggregates(T0 at the admission in intensive care unit)
- Kinetics of leukocyte-platelet aggregates formation(T0 at the admission in intensive care unit)